The GLP-1 Gold Rush Continues

A 2024 report from GlobalData has revealed that in spite of approaching headwinds in the obesity market, glucagon-like peptide-1 (GLP-1) receptor agonists will continue to… [Read More]

What’s Next in the Great GLP-1 Race?

 Roche Holding (RHHBY) joined the race to commercialize its own GLP-1 (glucagon-like peptide-1) receptor agonist drug this week, announcing that its dual-agonist asset, CT-388, had… [Read More]